Drug Discovery & Development
Harvard’s Wyss Institute spins out protein detection technology to create Spear Bio
The Wyss Institute for Biologically Inspired Engineering at Harvard University has licensed technology for detecting proteins in small patient samples to a newly formed startup. Read More
Lupus pill moves to clinical trial in humans after success in mice
Scientists at this week’s fall meeting of the American Chemical Society report they have begun phase II clinical trials of an oral pill containing a compound that in mice, not only prevented lupus-like symptoms, but also reversed signs of organ damage caused by the disease and prevented death. Read More
Analysis of nanoparticles, cancer cells could aid development of nanoparticle-based drugs
Researchers have identified biomarkers that predict whether different types of cancer cells will take up specific nanoparticles, potentially helping to overcome some obstacles to the development of nanoparticle-based drugs. Read More
Cell and gene therapy sector remains strong despite challenges: ARM CEO
The cell and gene therapy sector is “quite strong” despite the regulatory, investment, and manufacturing challenges facing the industry, according to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM). Lambert spoke with ScienceBoard.net about developments in the industry. Read More
Beta cell gene deletion stops type 1 diabetes in mice, suggesting new way to prevent disease
Deleting a proinflammatory gene in the beta cells of pre-diabetic mice stops the development of type 1 diabetes, pointing to a potential way to prevent the condition, according to a study published on June 28 in the journal Cell Reports. Read More
Manufacturing partnerships support high quality cell therapies
Chimeric Therapeutics, Ncardia, and Novartis are some of the companies that have decided to partner to make complex manufacturing processes more efficient for novel therapies, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Read More
Nivolumab/chemo combo will change lung cancer care
A new study that pairs neoadjuvant nivolumab with chemotherapy for patients with nonsmall cell lung cancer has the potential to revolutionize treatment, according to one expert. The research was presented April 11 at the American Association for Cancer Research 2022 meeting and published simultaneously in the New England Journal of Medicine. Read More
How diversity, inclusion help one company turn sci-fi into sci-fact
Juliana Blum, PhD, co-founder and executive vice president of corporate development at Humacyte, spoke with ScienceBoard about diversity and inclusion in the life sciences, especially about being a woman in science. Read More
Experience sharing is critical for women in science
Sharing experiences with future generations is key to moving science and biotechnology forward. As a female leader of a biotechnology company, Dr. Bridget Martell, CEO of Artizan Biosciences, shares her experiences and perspectives with ScienceBoard. Read More
Funding for cell and gene therapies exceeded $70B in 2021
Total funding from all sources for cell and gene therapy companies totaled $70.8 billion last year, according to the recent “Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments” report published by Kalorama Information, a sister company of ScienceBoard. Read More
Conferences
Glasgow International Health Festival
January 25-26, 2023
Glasgow
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter